KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to 21.01%.

  • Bristol Myers Squibb's EBIT Margin rose 165600.0% to 21.01% in Q4 2025 from the same period last year, while for Dec 2025 it was 9.56%, marking a year-over-year increase of 367000.0%. This contributed to the annual value of 9.56% for FY2025, which is 367100.0% up from last year.
  • Per Bristol Myers Squibb's latest filing, its EBIT Margin stood at 21.01% for Q4 2025, which was up 165600.0% from 2.63% recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's EBIT Margin ranged from a high of 1.8% in Q1 2023 and a low of 121.77% during Q1 2024
  • Moreover, its 5-year median value for EBIT Margin was 6.58% (2022), whereas its average is 14.01%.
  • Per our database at Business Quant, Bristol Myers Squibb's EBIT Margin tumbled by -1235700bps in 2024 and then skyrocketed by 1212200bps in 2025.
  • Quarter analysis of 5 years shows Bristol Myers Squibb's EBIT Margin stood at 4.16% in 2021, then plummeted by -55bps to 6.44% in 2022, then tumbled by -45bps to 9.33% in 2023, then crashed by -303bps to 37.57% in 2024, then skyrocketed by 44bps to 21.01% in 2025.
  • Its last three reported values are 21.01% in Q4 2025, 2.63% for Q3 2025, and 13.03% during Q2 2025.